Cost Effectiveness Analysis of Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia from the Health Insurance Perspective in Egypt

Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2225
https://www.valueinhealthjournal.com/article/S1098-3015(16)33591-4/fulltext
Title : Cost Effectiveness Analysis of Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia from the Health Insurance Perspective in Egypt
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33591-4&doi=10.1016/j.jval.2016.09.2225
First page : A735
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 2110
Categories :
Tags :
Regions :
ViH Article Tags :